Hanwha Impact has a vision of making a positive impact on the globe and humanity for a sustainable future through technical innovation. Inari Agriculture uses Artificial Intelligence (AI) and gene editing to develop seeds that generate a smaller carbon footprint and increase yield by using 40% less water and fertilizer. In 2021, Hanwha Impact invested in Inari Agriculture, an AgTech firm utilizing gene-editing technology. “The funds raised this time will be used to realize the potential cure for genetic diseases.”
“Tessera’s Gene Writing™ platform aims to develop a fundamentally different technology than conventional gene therapeutics,” said Noubar Afeyan, the co-founder and chairman of Tessera and Moderna and the founder and CEO of Flagship Pioneering. Gene Writing™ could lead to a cure for all manner of genetic disorders, including those that are rare and currently untreatable with existing genetic technologies. The company’s technology can change base pairs, make small insertions or deletions, and integrate entire genes into the genome.
#Tessera therapeutics stock code#
As the technology supports the design and testing of numerous natural and synthetic MGEs, Gene Writing™ is perceived to be more accurate and efficient than the existing gene correction techniques using CRISPR/Cas92.īy targeting DNA, the code of life and cause of genetic diseases, Gene Writing™ can write into or rewrite the genome to treat health conditions at their source. Tessera is known for its next-generation gene correction technology platform called Gene Writing™, which utilizes Mobile Genetic Elements (MGEs)1 to overcome the limitations of existing technology.
#Tessera therapeutics stock series#
Tessera recently secured $300 million in a Series C financing, the fourth stage of startup financing that focuses on scaling successful companies, where Hanwha Impact participated as an investor. The company was founded in 2018 by Flagship Pioneering, the investor behind COVID-19 vaccine maker Moderna. Hanwha Impact recently announced its investment in Tessera Therapeutics, an American life sciences company that is pioneering a new category of genome engineering technology and establishing a new field of genetic medicine. Hanwha Impact Invests in Gene Writing™ Pioneer Tessera Therapeutics to Drive the Future of Genetic Medicine
0 kommentar(er)
